TBC1 domain family member 3 (TBC1D3)

TBC1 domain family member 3 (TBC1D3) is a primate-specific protein containing a TBC (Tre-2, Bub2, Cdc16) domain, typically associated with Rab GTPase-activating proteins (Rab-GAPs).[1][2][3] However, TBC1D3 lacks critical catalytic residues and, unlike classical Rab-GAPs, exhibits little or no intrinsic GTPase-activating protein activity.[1] TBC1D3 functions in the regulation of macropinocytosis, particularly by facilitating epidermal growth factor (EGF)-mediated macropinocytosis through a pathway involving ARF6 and RAB5, and interacts with the ARF6 effector GGA3.[1] This protein emerged during primate evolution via gene duplication and has expanded copy number in humans. TBC1D3 has been linked to cancer, especially prostate cancer, and polycystic kidney disease by genetic association, but no targeted drugs or established clinical biomarkers are known.[3][4] While annotated as a predicted Rab-GAP, its primary biological effect is to optimize signal propagation for endocytic and macropinocytic pathways instead of direct enzymatic activity. TBC1D3 is most often studied in cellular trafficking and oncogenesis contexts and is not a classical drug target or receptor.[1][3]

Other names

PRC17TBC1D3ADKFZp434P2235Prostate cancer gene 17 proteinProtein TRE17-alphaRab GTPase-activating protein PRC17TBC1D3CTBC1D3DTBC1D3FTBC1D3LTBC1 domain family member 3CTBC1 domain family member 3LTBC1 domain family member 3FTBC1D3G